Mevrometostat plus enzalutamide in metastatic castration-resistant
Mevrometostat plus enzalutamide in metastatic castration-resistant prostate cancer
$26.04PFE last close Jun 16Pfizer ($PFE)
$26.04PFE last close Jun 16Closed
Will PF-06821497 (mevrometostat) with enzalutamide meet the primary endpoint of radiographic progression-free survival (rPFSOutcome measureProgression-Free Survival (PFS)rPFS is defined as the time from randomization to first objective evidence of radiographic progression by RECIST v1.1 or PCWG3 guidelines by blinded independent central review, or death, whichever occurs first.Primary outcome | Randomization up to approximately 3 yearsClinicalTrials.gov outcome) in NCT06629779?
Paper Trading
Create account to trade- Resolved Date
- 12/2/26
- Study Completion
- 11/30/28
- Sponsor
- Ticker
- $PFE
- Type
- Trial Status
- RECRUITING
- Trial Size
- 900
- NCT
- NCT06629779
- Trial Description
- This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide works better than enzalutamide alone in participants with metastatic castration-resistant prostate cancer who are ARSi or abiraterone naive.